Clinical characteristics of patients carrying different genotypes
. | Sex, (m/f) . | Indication, v/a/o . | Mean age when OAT started, y (SD) . | Mean time in OAT, y (SD) . | Warfarin mean daily dose, mg (SD) . | Mean INR (SD) . | Patients taking other drugs, % (n) . | Visits, n (SD) . |
|---|---|---|---|---|---|---|---|---|
| VKORC1 | ||||||||
| 1173C>T | ||||||||
| CC, n = 54, 36.8% | 32/22 | 42/8/4 | 42.8 (16.5) | 1.9 (2.9) | 7.0 (3.0)* | 2.45 (0.39) | 35.2 (19) | 28.4 (24.0) |
| CT, n = 69, 46.9% | 34/35 | 55/8/6 | 43.4 (16.0) | 1.5 (1.4) | 5.1 (2.5)* | 2.56 (0.39) | 37.7 (26) | 27.3 (23.7) |
| TT, n = 24, 16.3% | 14/10 | 15/5/4 | 49.6 (18.4) | 1.3 (1.2) | 3.7 (1.6) | 2.53 (0.37) | 45.8 (11) | 25.2 (20.1) |
| 3730G>A | ||||||||
| GG, n = 67, 45.5% | 31/36 | 49/11/7 | 44.2 (18.0) | 1.5 (1.3) | 5.2 (2.6)† | 2.52 (0.35) | 42.7 (23) | 26.6 (21.9) |
| GA, n = 58, 39.5% | 35/23 | 42/11/5 | 46.2 (15.1) | 1.7 (2.8) | 5.3 (2.2) | 2.60 (0.45) | 24.3 (25) | 25.5 (21.6) |
| AA, n = 22, 15.0% | 14/8 | 21/1/0 | 44.3 (16.5) | 1.6 (1.6) | 6.9 (4.0) | 2.38 (0.31) | 36.6 (7) | 28.9 (26.6) |
| CYP2C9 | ||||||||
| Allele*1, n = 74, 50.3% | 44/30 | 56/11/7 | 41.9 (15.3)‡ | 1.8 (2.5) | 6.6 (2.9) | 2.47 (0.36) | 36.5 (27) | 27.7 (22.3) |
| Allele*2, n = 48, 32.0% | 25/23 | 37/6/5 | 44.5 (17.6) | 1.7 (1.5) | 5.1 (2.2)§ | 2.58 (0.41) | 37.5 (18) | 28.2 (23.2) |
| Allele*3, n = 23, 16.3% | 11/12 | 18/4/1 | 47.9 (16.7) | 1.2 (1.3) | 3.5 (1.9)§ | 2.63 (0.44) | 39.1 (9) | 22.3 (22.2) |
| Allele*2 + Allele*3, n = 2, 1.4% | 0/2 | 1/0/1 | 76.5 (9.2) | 2.3 (2.7) | 1.8 (0.1)§ | 3.00 (0.21) | 100.0 (2) | 55.0 (58.0) |
. | Sex, (m/f) . | Indication, v/a/o . | Mean age when OAT started, y (SD) . | Mean time in OAT, y (SD) . | Warfarin mean daily dose, mg (SD) . | Mean INR (SD) . | Patients taking other drugs, % (n) . | Visits, n (SD) . |
|---|---|---|---|---|---|---|---|---|
| VKORC1 | ||||||||
| 1173C>T | ||||||||
| CC, n = 54, 36.8% | 32/22 | 42/8/4 | 42.8 (16.5) | 1.9 (2.9) | 7.0 (3.0)* | 2.45 (0.39) | 35.2 (19) | 28.4 (24.0) |
| CT, n = 69, 46.9% | 34/35 | 55/8/6 | 43.4 (16.0) | 1.5 (1.4) | 5.1 (2.5)* | 2.56 (0.39) | 37.7 (26) | 27.3 (23.7) |
| TT, n = 24, 16.3% | 14/10 | 15/5/4 | 49.6 (18.4) | 1.3 (1.2) | 3.7 (1.6) | 2.53 (0.37) | 45.8 (11) | 25.2 (20.1) |
| 3730G>A | ||||||||
| GG, n = 67, 45.5% | 31/36 | 49/11/7 | 44.2 (18.0) | 1.5 (1.3) | 5.2 (2.6)† | 2.52 (0.35) | 42.7 (23) | 26.6 (21.9) |
| GA, n = 58, 39.5% | 35/23 | 42/11/5 | 46.2 (15.1) | 1.7 (2.8) | 5.3 (2.2) | 2.60 (0.45) | 24.3 (25) | 25.5 (21.6) |
| AA, n = 22, 15.0% | 14/8 | 21/1/0 | 44.3 (16.5) | 1.6 (1.6) | 6.9 (4.0) | 2.38 (0.31) | 36.6 (7) | 28.9 (26.6) |
| CYP2C9 | ||||||||
| Allele*1, n = 74, 50.3% | 44/30 | 56/11/7 | 41.9 (15.3)‡ | 1.8 (2.5) | 6.6 (2.9) | 2.47 (0.36) | 36.5 (27) | 27.7 (22.3) |
| Allele*2, n = 48, 32.0% | 25/23 | 37/6/5 | 44.5 (17.6) | 1.7 (1.5) | 5.1 (2.2)§ | 2.58 (0.41) | 37.5 (18) | 28.2 (23.2) |
| Allele*3, n = 23, 16.3% | 11/12 | 18/4/1 | 47.9 (16.7) | 1.2 (1.3) | 3.5 (1.9)§ | 2.63 (0.44) | 39.1 (9) | 22.3 (22.2) |
| Allele*2 + Allele*3, n = 2, 1.4% | 0/2 | 1/0/1 | 76.5 (9.2) | 2.3 (2.7) | 1.8 (0.1)§ | 3.00 (0.21) | 100.0 (2) | 55.0 (58.0) |
v/a/o indicates patients with previous venous (v) or arterial (a) thrombosis, or other (o) disease requiring oral anticoagulation; OAT, oral anticoagulant therapy.
P < .001 vs TT carriers (Scheffé test)
P < .05 vs AA carriers (Mann-Whitney U test).
P < .05 vs CYP2C9*2 + CYP2C9*3 carriers (Scheffé test).
P < .05 vs CYP2C9*1 carriers (Scheffé test).